Aptose Biosciences (APTO) Competitors $0.28 +0.11 (+63.92%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends APTO vs. DYAI, ESLA, PASG, CVM, ACHL, DTIL, ELEV, SABS, OKYO, and OTLKShould you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Dyadic International (DYAI), Estrella Immunopharma (ESLA), Passage Bio (PASG), CEL-SCI (CVM), Achilles Therapeutics (ACHL), Precision BioSciences (DTIL), Elevation Oncology (ELEV), SAB Biotherapeutics (SABS), OKYO Pharma (OKYO), and Outlook Therapeutics (OTLK). These companies are all part of the "biological products, except diagnostic" industry. Aptose Biosciences vs. Dyadic International Estrella Immunopharma Passage Bio CEL-SCI Achilles Therapeutics Precision BioSciences Elevation Oncology SAB Biotherapeutics OKYO Pharma Outlook Therapeutics Dyadic International (NASDAQ:DYAI) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Which has more volatility and risk, DYAI or APTO? Dyadic International has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Does the media refer more to DYAI or APTO? In the previous week, Aptose Biosciences had 5 more articles in the media than Dyadic International. MarketBeat recorded 5 mentions for Aptose Biosciences and 0 mentions for Dyadic International. Aptose Biosciences' average media sentiment score of 0.09 beat Dyadic International's score of 0.00 indicating that Aptose Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Dyadic International Neutral Aptose Biosciences Neutral Do analysts prefer DYAI or APTO? Dyadic International currently has a consensus target price of $6.00, indicating a potential upside of 242.86%. Aptose Biosciences has a consensus target price of $4.33, indicating a potential upside of 1,453.17%. Given Aptose Biosciences' higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Dyadic International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aptose Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in DYAI or APTO? Aptose Biosciences received 219 more outperform votes than Dyadic International when rated by MarketBeat users. However, 64.40% of users gave Dyadic International an outperform vote while only 63.12% of users gave Aptose Biosciences an outperform vote. CompanyUnderperformOutperformDyadic InternationalOutperform Votes16164.40% Underperform Votes8935.60% Aptose BiosciencesOutperform Votes38063.12% Underperform Votes22236.88% Which has preferable valuation and earnings, DYAI or APTO? Dyadic International has higher revenue and earnings than Aptose Biosciences. Dyadic International is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyadic International$3.36M15.39-$6.80M-$0.23-7.61Aptose BiosciencesN/AN/A-$51.21M-$2.97-0.09 Is DYAI or APTO more profitable? Aptose Biosciences has a net margin of 0.00% compared to Dyadic International's net margin of -188.09%. Dyadic International's return on equity of -149.16% beat Aptose Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Dyadic International-188.09% -149.16% -59.81% Aptose Biosciences N/A -5,683.22%-300.44% Do institutionals and insiders believe in DYAI or APTO? 28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are owned by institutional investors. 28.8% of Dyadic International shares are owned by company insiders. Comparatively, 3.9% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryDyadic International and Aptose Biosciences tied by winning 8 of the 16 factors compared between the two stocks. Ad Investors AlleyCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…Click here to discover the new #1 way to invest in Tesla Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APTO vs. The Competition Export to ExcelMetricAptose BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.79M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-0.0946.7390.1317.19Price / SalesN/A415.011,116.25117.01Price / CashN/A182.1043.1037.85Price / Book-1.473.894.784.78Net Income-$51.21M-$42.21M$120.31M$225.60M7 Day Performance44.56%-2.15%-1.92%-1.23%1 Month Performance46.84%1.73%13.65%0.46%1 Year Performance-87.97%16.36%28.34%15.24% Aptose Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APTOAptose Biosciences2.6342 of 5 stars$0.28+63.9%$4.33+1,453.2%-87.7%$16.79MN/A-0.0931News CoverageGap UpHigh Trading VolumeDYAIDyadic International1.6358 of 5 stars$1.49-8.6%$6.00+302.7%+12.9%$44.09M$3.36M-7.097Gap DownESLAEstrella Immunopharma0.1512 of 5 stars$1.21+1.6%N/A-6.5%$43.87MN/A-4.50N/AGap DownPASGPassage Bio2.6838 of 5 stars$0.71-6.5%$7.75+991.5%-27.6%$43.86MN/A0.00130CVMCEL-SCIN/A$0.67-2.6%N/A-72.7%$42.87MN/A-1.1943News CoverageGap DownACHLAchilles Therapeutics2.9893 of 5 stars$1.00+1.0%$4.00+300.0%+18.0%$41.10MN/A-0.60250DTILPrecision BioSciences4.4761 of 5 stars$5.08-6.6%$39.50+677.6%-55.5%$38.97M$75.10M90.67200Positive NewsELEVElevation Oncology1.9868 of 5 stars$0.64+0.8%$7.20+1,023.2%+30.0%$37.90MN/A-0.7840Analyst ForecastSABSSAB Biotherapeutics2.4238 of 5 stars$4.01-1.7%$12.40+209.2%+532.7%$37.01M$2.24M0.00140Gap UpOKYOOKYO Pharma1.5557 of 5 stars$1.02-3.8%$7.00+586.3%-38.4%$34.52MN/A0.007Gap DownOTLKOutlook Therapeutics1.8305 of 5 stars$1.42-4.1%$42.34+2,881.9%-83.2%$33.60MN/A0.0020 Related Companies and Tools Related Companies Dyadic International Competitors Estrella Immunopharma Competitors Passage Bio Competitors CEL-SCI Competitors Achilles Therapeutics Competitors Precision BioSciences Competitors Elevation Oncology Competitors SAB Biotherapeutics Competitors OKYO Pharma Competitors Outlook Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APTO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APTO Stock Alerts